Tium Bio

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company based in Seongnam-si, South Korea focused on discovering and developing innovative small molecule and biologic therapeutics for patients with rare and incurable diseases. Its lead pipeline assets include TU2218, an oral immuno-oncology therapy targeting TGF-beta and VEGFR2 currently in Phase 2 trials, TU2670, an orally active GnRH antagonist for uterine fibroids and assisted reproduction, and TU7710, a bypass-factor therapy for hemophilia patients with inhibitors. TiumBio serves oncology, rare disease, and women's health patient populations globally and operates subsidiaries including Boston-based Initium Therapeutics and CDMO company Protium Science.